Gloria D Coronado1, William M Vollmer2, Amanda Petrik3, Stephen H Taplin4, Timothy E Burdick5, Richard T Meenan6, Beverly B Green7. 1. The Center for Health Research, Kaiser Permanente Northwest, 3800 N. Interstate Avenue, Portland, OR 97227, USA. Electronic address: Gloria.d.coronado@kpchr.org. 2. The Center for Health Research, Kaiser Permanente Northwest, 3800 N. Interstate Avenue, Portland, OR 97227, USA. Electronic address: William.vollmer@kpchr.org. 3. The Center for Health Research, Kaiser Permanente Northwest, 3800 N. Interstate Avenue, Portland, OR 97227, USA. Electronic address: Amanda.f.petrik@kpchr.org. 4. National Cancer Institute, Process of Care Research Branch, Behavioral Research Program, Division of Cancer Control and Population Sciences, 9609 Medical Center Drive, Bethesda, MD 20892-9760, USA. Electronic address: Taplins@mail.nih.gov. 5. OCHIN, Inc., 1881 SW Naito Parkway, Portland, OR 97201, USA; Department of Family Medicine Oregon Health & Sciences University, 4411 SW Vermont Street, Portland, OR 97219, USA. Electronic address: burdickt@ochin.org. 6. The Center for Health Research, Kaiser Permanente Northwest, 3800 N. Interstate Avenue, Portland, OR 97227, USA. Electronic address: Richard.meenan@kpchr.org. 7. Group Health Research Institute, 1730 Minor Avenue, Suite 1600, Seattle, WA 98101, USA. Electronic address: Green.b@ghc.org.
Abstract
BACKGROUND: Colorectal cancer is the second-leading cause of cancer deaths in the United States. The Strategies and Opportunities to Stop Colorectal Cancer (STOP CRC) in Priority Populations study is a pragmatic trial and a collaboration between two research institutions and a network of more than 200 safety net clinics. The study will assess the effectiveness of a system-based intervention designed to improve the rates of colorectal-cancer screening using fecal immunochemical testing (FIT) in federally qualified health centers in Oregon and Northern California. MATERIAL AND METHODS:STOP CRC is a cluster-randomized comparative-effectiveness pragmatic trial enrolling 26 clinics. Clinics will be randomized to one of two arms. Clinics in the intervention arm (1) will use an automated, data-driven, electronic health record-embedded program to identify patients due for colorectal screening and mail FIT kits (with pictographic instructions) to them; (2) will conduct an improvement process (e.g. Plan-Do-Study-Act) to enhance the adoption, reach, and effectiveness of the program. Clinics in the control arm will provide opportunistic colorectal-cancer screening to patients at clinic visits. The primary outcomes are: proportion of age- and screening-eligible patients completing a FIT within 12months; and cost, cost-effectiveness, and return on investment of the intervention. CONCLUSIONS: This large-scale pragmatic trial will leverage electronic health record information and existing clinic staff to enroll a broad range of patients, including many with historically low colorectal-cancer screening rates. If successful, the program will provide a model for a cost-effective and scalable method to raise colorectal-cancer screening rates.
RCT Entities:
BACKGROUND:Colorectal cancer is the second-leading cause of cancer deaths in the United States. The Strategies and Opportunities to Stop Colorectal Cancer (STOP CRC) in Priority Populations study is a pragmatic trial and a collaboration between two research institutions and a network of more than 200 safety net clinics. The study will assess the effectiveness of a system-based intervention designed to improve the rates of colorectal-cancer screening using fecal immunochemical testing (FIT) in federally qualified health centers in Oregon and Northern California. MATERIAL AND METHODS: STOP CRC is a cluster-randomized comparative-effectiveness pragmatic trial enrolling 26 clinics. Clinics will be randomized to one of two arms. Clinics in the intervention arm (1) will use an automated, data-driven, electronic health record-embedded program to identify patients due for colorectal screening and mail FIT kits (with pictographic instructions) to them; (2) will conduct an improvement process (e.g. Plan-Do-Study-Act) to enhance the adoption, reach, and effectiveness of the program. Clinics in the control arm will provide opportunistic colorectal-cancer screening to patients at clinic visits. The primary outcomes are: proportion of age- and screening-eligible patients completing a FIT within 12months; and cost, cost-effectiveness, and return on investment of the intervention. CONCLUSIONS: This large-scale pragmatic trial will leverage electronic health record information and existing clinic staff to enroll a broad range of patients, including many with historically low colorectal-cancer screening rates. If successful, the program will provide a model for a cost-effective and scalable method to raise colorectal-cancer screening rates.
Authors: Iris Vogelaar; Marjolein van Ballegooijen; Deborah Schrag; Rob Boer; Sidney J Winawer; J Dik F Habbema; Ann G Zauber Journal: Cancer Date: 2006-10-01 Impact factor: 6.860
Authors: Joan S Ash; Dean F Sittig; Carmit K McMullen; Kenneth Guappone; Richard Dykstra; James Carpenter Journal: AMIA Annu Symp Proc Date: 2008-11-06
Authors: Gloria D Coronado; Jen Sanchez; Amanda Petrik; Tanya Kapka; Jen DeVoe; Beverly Green Journal: J Cancer Educ Date: 2014-03 Impact factor: 2.037
Authors: Ronald E Myers; Randa Sifri; Terry Hyslop; Michael Rosenthal; Sally W Vernon; James Cocroft; Thomas Wolf; Jocelyn Andrel; Richard Wender Journal: Cancer Date: 2007-11-01 Impact factor: 6.860
Authors: Sanja Percac-Lima; Richard W Grant; Alexander R Green; Jeffrey M Ashburner; Gloria Gamba; Sarah Oo; James M Richter; Steven J Atlas Journal: J Gen Intern Med Date: 2009-02 Impact factor: 5.128
Authors: Bernard Levin; David A Lieberman; Beth McFarland; Robert A Smith; Durado Brooks; Kimberly S Andrews; Chiranjeev Dash; Francis M Giardiello; Seth Glick; Theodore R Levin; Perry Pickhardt; Douglas K Rex; Alan Thorson; Sidney J Winawer Journal: CA Cancer J Clin Date: 2008-03-05 Impact factor: 508.702
Authors: Gloria D Coronado; William M Vollmer; Amanda Petrik; Josue Aguirre; Tanya Kapka; Jennifer Devoe; Jon Puro; Tran Miers; Jennifer Lembach; Ann Turner; Jennifer Sanchez; Sally Retecki; Christine Nelson; Beverly Green Journal: BMC Cancer Date: 2014-02-26 Impact factor: 4.430
Authors: Gloria D Coronado; Jennifer L Schneider; Amanda Petrik; Jennifer Rivelli; Stephen Taplin; Beverly B Green Journal: Transl Behav Med Date: 2017-09 Impact factor: 3.046
Authors: Jennifer K Coury; Jennifer L Schneider; Beverly B Green; Laura-Mae Baldwin; Amanda F Petrik; Jennifer S Rivelli; Malaika R Schwartz; Gloria D Coronado Journal: Transl Behav Med Date: 2020-02-03 Impact factor: 3.046
Authors: Amanda F Petrik; Beverly B Green; William M Vollmer; Thuy Le; Barbara Bachman; Erin Keast; Jennifer Rivelli; Gloria D Coronado Journal: Fam Pract Date: 2016-07-28 Impact factor: 2.267
Authors: Fan Li; Elizabeth L Turner; Patrick J Heagerty; David M Murray; William M Vollmer; Elizabeth R DeLong Journal: Stat Med Date: 2017-08-07 Impact factor: 2.373
Authors: Deven McGraw; Sarah M Greene; Caroline S Miner; Karen L Staman; Mary Jane Welch; Alan Rubel Journal: Clin Trials Date: 2015-09-15 Impact factor: 2.486
Authors: Andrea J Cook; Elizabeth Delong; David M Murray; William M Vollmer; Patrick J Heagerty Journal: Clin Trials Date: 2016-05-13 Impact factor: 2.486
Authors: Carrie M Nielson; William M Vollmer; Amanda F Petrik; Erin M Keast; Beverly B Green; Gloria D Coronado Journal: J Gen Intern Med Date: 2019-01-25 Impact factor: 5.128
Authors: Gloria D Coronado; Amanda F Petrik; William M Vollmer; Stephen H Taplin; Erin M Keast; Scott Fields; Beverly B Green Journal: JAMA Intern Med Date: 2018-09-01 Impact factor: 21.873